The Zhitong Finance App learned that MSD (MRK.US) announced today that its “first-in-class” treatment, Winrevair (sotatercept), reached a major end in the mid-term analysis of the phase 3 clinical trial ZENITH. Based on this positive outcome, the trial will be terminated early to allow all patients with pulmonary hypertension (PAH) the opportunity to receive Winrevair treatment. It is worth mentioning that this treatment was rated by industry media Evaluate as one of the potentially blockbuster treatments expected to be approved in 2024.

The Zhitong Finance App learned that MSD (MRK.US) announced today that its “first-in-class” treatment, Winrevair (sotatercept), reached a major end in the mid-term analysis of the phase 3 clinical trial ZENITH. Based on this positive outcome, the trial will be terminated early to allow all patients with pulmonary hypertension (PAH) the opportunity to receive Winrevair treatment. It is worth mentioning that this treatment was rated by industry media Evaluate as one of the potentially blockbuster treatments expected to be approved in 2024.